Gambro and Dipylon Medical AB (Dipylon), a Swedish medical device company with focus on cardiac monitoring, have signed an exclusive supply and development agreement.

Through the agreement, Dipylon is granted exclusive rights to Gambro’s advanced membrane technology for use in its diagnostic catheters intended for cardiac monitoring.

The Dipylon Cardiac Catheter system enables early detection of potentially life-threatening ischemic complications following heart surgery. “Gambro is very excited to co-operate with Dipylon in developing their cardiac monitoring system. The collaboration offers Gambro the opportunity to leverage its leading membrane technology know-how into new diagnostic and therapeutic application areas.” says Patrick Greatrex, Vice President Business Development at Gambro.

Heart disease is by far the most common cause of death in the Western World. Globally, nearly two million heart surgeries are performed each year. 30,000 of these patients will die from ischemic complications following surgery and there is today no reliable method to detect these complications. “Gambro’s world-leading expertise in membrane technology has been instrumental in the development of our unique system. The collaboration has enabled us to launch the system, celebrate our first export success and raise additional growth capital financing to enable full commercialization.” says Måns Alfvén, CEO of Dipylon. 

The system consists of a catheter which is implanted into the venous outflow of the heart, whereby Gambro’s membrane technology is used to monitor biochemical processes which are predicative of infarcts and heart failure. The system is cleared for up to 48 hours of continuous monitoring and intended for intensive care use. “We have tested several types of membranes but Gambro’s is the only type we have found that can stay in blood for several days with full functionality and without any signs of complications.” says Henrik Falkén, Managing Director of Dipylon. 

For further information please contact: 

Maria Lundbäck, Gambro, Acting Head of Corporate Communications, tel. +46 705 13 65 34
Patrick Greatrex, Gambro, Vice President Business Development, Tel: +46 733 16 94 69
Måns Alfvén, CEO, Dipylon Medical AB, Tel: +46 707 81 21 99